Quizartinib, a potent and specific oral FLT3 inhibitor, exerts an anti-cancer effect by inhibiting the activity of the mutation-activated FLT3, which causes tumor cells to undergo apoptosis (Naqvi and Ravandi 2019). The gene discussed is FLT3; the disease is neoplasm.